LCM
MGX icon

Laurion Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Laurion Capital Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$211K – 788
2024
Q1 		$211K Buy
+20,000
New +$230K ﹤0.01% 467

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laurion Capital Management's MGX Position: Q2 2024 in Review

Laurion Capital Management sold out of Metagenomi Therapeutics (MGX) in Q2 2024, closing a stake of 20,000 shares — an estimated $211K sold.

Laurion Capital Management first reported a position in MGX in Q1 2024 and held it in 1 quarter. The position peaked at $211K in Q1 2024. 54 funds tracked by Wall St. Rank hold MGX as of Q2 2024.

  • Laurion Capital Management reported no remaining Metagenomi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 20,000 Metagenomi Therapeutics shares in Q2 2024, an estimated $211K.
  • Laurion Capital Management first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 1 quarter.
  • Laurion Capital Management's Metagenomi Therapeutics position peaked at $211K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.